Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening
- 1 October 2002
- Vol. 60 (4) , 42-46
- https://doi.org/10.1016/s0090-4295(02)01694-1
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographicsUrology, 2001
- USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND α1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCERJournal of Urology, 2000
- Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.JAMA, 2000
- Systematic Overview of Cost-Utility Assessments in OncologyJournal of Clinical Oncology, 2000
- COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCERJournal of Urology, 2000
- ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulationUrology, 2000
- Prostate-specific antigenSeminars in Surgical Oncology, 2000
- Cost‐effectiveness analysis in early detection of prostate cancer: An evaluation of six screening strategies in a randomly selected population of 2,400 menThe Prostate, 1995